Association of Reproductive Health Professionals
Association of Reproductive Health Professionals
Reproductive Health Topics Publications & Resources Professional Education Newsroom Membership Policy & Advocacy About Us
Quick Reference Guide for Clinicians
Send To A Friend Send To A Friend Bookmark this Page Share this page
Hot Topics in Sexually Transmitted Infections and Associated Conditions

(Published November 2013)

References

  1. World Health Organization. Prevalence and incidence of selected sexually transmitted infections: Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Geneva: World Health Organization; 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241502450_eng.pdf.
  2. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among U.S. women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93.
  3. Owusu-Edusei K, Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis. 2013;40(3):197–201.
  4. Lusti-Narasimhan M, Ndowa F, Pires SS. Importance of sexually transmitted infections in funding for HIV within proposals to the Global Fund. Sex Transm Infect. 2011;87 Suppl 2:ii19–22.
  5. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6–10.
  6. Centers for Disease Control and Prevention. Sexually transmitted diseases in the United States, 2008: health consequences of untreated chlamydia and gonorrhea. No date. Available from: http://www.cdc.gov/std/stats08/trends.htm.
  7. National Network of STD/HIV Prevention Training Centers. Brief, individual behavioral counseling for STD/HIV risk reduction. 2011. Available from: http://nnptc.org/wp-content/uploads/Behavioral-Counseling-Risk-Reduction-Curriculum-Module-2011.pdf.
  8. Pillai AS, Sprockel PT, Barthmare SC. Tips for talking with teens about STDs. J Fam Pract. 2009;58(2):76–81.
  9. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1–116.
  10. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291:1368–79.
  11. Cotch MF, Pastorek JG, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis. 1997;24:353–60.
  12. Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. 2002;34:519–22.
  13. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2011. Atlanta, GA: US Department of Health and Human Services; 2012.
  14. Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med. 2007;147(2):89–96.
  15. Lyss SB, Kamb ML, Peterman TA, et al. Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann Intern Med. 2003;139(3):178–85.
  16. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61(31):590–4.
  17. U.S. Preventive Services Task Force. Screening for gonorrhea: recommendation statement. Ann Fam Med. 2005;3:263–7.
  18. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296:964–73.
  19. Kimberlin DW, Rouse DJ. Clinical practice: genital herpes. N Engl J Med. 2004;350(19):1970–7.
  20. Engelberg R, Carrell D, Krantz E, et al. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis. 2003;30:174–7.
  21. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121:847–54.
  22. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1–110.
  23. Ashley RL, Eagleton M, Pfeiffer N. Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection. J Clin Microbiol. 1999;37:1632–3.
  24. Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis. 2003;30:310–4.
  25. Van Wagoner NJ, Hook EW 3rd. Herpes diagnostic tests and their use. Curr Infect Dis Rep. 2012;14(2):175–84.
  26. Van Der Pol B, Warren T, Taylor SN, et al. Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification test. J Clin Microbiol. 2012;50(11):3466–71.
  27. National Network of STD/HIV Prevention Training Centers. Genital and perirectal herpes simplex virus infection. 2012. Available from: http://nnptc.org/wp-content/uploads/NNPTC-Core-Curriculum-Herpes_20122.pdf.
  28. Strick LB, Wald A. Diagnostics for herpes simplex virus: is PCR the new gold standard? Mol Diagn Ther. 2006;10:17–28.
  29. World Health Organization. HIV fact sheet. Available from: http://www.who.int/mediacentre/factsheets/fs360/en/index.html.
  30. Centers for Disease Control and Prevention. HIV in the United States: at a glance. 2013. Available from: http://www.cdc.gov/hiv/pdf/statistics_basics_factsheet.pdf.
  31. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2010. HIV Surveillance Supplemental Report. 2012;17(3, pt A). Available from: http://www.cdc.gov/hiv/surveillance/resources/reports/2010supp_vol17no3/index.htm.
  32. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report. 2012;17(4). Available from: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/#supplemental.
  33. Purcell D, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. Open AIDS Journal. 2012;6 Suppl 1: M6:98–107. Available from: http://www.benthamscience.com/open/toaidj/articles/V006/SI0065TOAIDJ/98TOAIDJ.pdf.
  34. Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. Morb Mortal Wkly Rep. 2011;60:689–93.
  35. Hallfors DD, Iritani BJ, Miller WC, et al. Sexual and drug behavior patterns and HIV and STD racial disparities: the need for new directions. Am J Pub Health. 2007;97(1):125–32.
  36. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS ONE. 2011;6(8):e17502.
  37. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2005. Vol. 17, Rev. ed. 2007:1–54.
  38. Henderson SJ, Bernstein LB, George DM, et al. Older women and HIV: how much do they know and where are they getting their information? J Am Geriatr Soc. 2004;52:1549–53.
  39. Lindau ST, Leitsch SA, Lundberg KL, et al. Older women’s attitudes, behavior, and communication about sex and HIV: a community based study. J Womens Health. 2006;6:747–53.
  40. Center for AIDS Prevention Studies. What are HIV prevention needs of adults over 50? [fact sheet 29E]. 1997. Available from: http://caps.ucsf.edu/uploads/pubs/FS/pdf/over50FS.pdf.
  41. Centers for Disease Control and Prevention. HIV among youth. 2013. Available from: http://www.cdc.gov/hiv/risk/age/youth/index.html.
  42. Centers for Disease Control and Prevention. Youth risk behavior surveillance—United States, 2011. Morb Mortal Wkly Rep. 2012;61(SS-4).
  43. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75(1):3–17.
  44. Wasserheit JN. 1992. Epidemiologic synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. SexTransm Dis. 9:61–77.
  45. Centers for Disease Control and Prevention. The role of STD detection and treatment in HIV prevention—CDC fact sheet. 2010. Available from: http://www.cdc.gov/std/hiv/stdfact-std-hiv.htm.
  46. U.S. Preventive Services Task Force. Recommendation statement: Screening for HIV. 2013. Available from: http://www.uspreventiveservicestaskforce.org/uspstf13/hiv/hivfinalrs.htm#ref10.
  47. Centers for Disease Control and Prevention. Expedited partner therapy in the management of sexually transmitted diseases. Atlanta, GA: US Department of Health and Human Services; 2006.
  48. National Institutes of Health. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2013. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf:B1.
  49. New York State Department of Health. Guidelines for integrating domestic violence screening into HIV counseling, testing, referral & partner notification. Available from: http://www.health.ny.gov/nysdoh/rfa/hiv/guide.htm.
  50. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler, CM; ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11):1582–9.
  51. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100:513–7.
  52. Centers for Disease Control and Prevention. Genital HPV fact sheet. 2013. Available from: http://www.cdc.gov/std/hpv/stdfact-hpv.htm.
  53. Soper D. Reducing the health burden of HPV infection through vaccination. Infect Dis Obstet Gynecol. 2006;14:1–5.
  54. Bosch FX, de Sanjos S. Chapter 1: human papillomavirus and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3–13.
  55. Harper DM, Ranco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–55.
  56. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56(RR-2):1–24.
  57. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564–71.
  58. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43.
  59. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommendations on the use of quadrivalent human papillomavirus vaccine in males—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60(50):1705–8.
  60. Food and Drug Administration. Gardasil vaccine safety: information from CDC and FDA on the safety of Gardasil vaccine. Available from: www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm179549.htm.
  61. Food and Drug Administration. Package insert for Gardasil. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf.
  62. Food and Drug Administration. Package insert for Cervarix. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf.
  63. Centers for Disease Control and Prevention. Frequently asked questions about HPV vaccine safety. Available from: www.cdc.gov/vaccinesafety/Vaccines/HPV/hpv_faqs.html.
  64. Centers for Disease Control and Prevention. HPV vaccine information for clinicians—Fact sheet. Available from: www.cdc.gov/std/HPV/STDFact-HPV-vaccine-hcp.htm.
  65. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010;59(20):626–9.
  66. Lehtinen M, Paavonen J, Wheeler CM, et al. HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomized, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.
  67. Davis K, Dickman ED, Ferris D, et al. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8(3):188–94.
  68. Centers for Disease Control and Prevention. Condoms and STDs: Fact sheet for public health personnel. Available from: http://www.cdc.gov/condomeffectiveness/latex.htm.
  69. American Society for Colposcopy and Cervical Pathology. Diagnosis of HPV-induced disease: Cervical intraepithelial neoplasia grades 1, 2, 3 (CIN1, 2, and 3). Available from: http://www.asccp.org/practicemanagement/hpv/diagnosisofhpvinduceddisease/tabid/5825/default.aspx.
  70. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516–42.
  71. Centers for Disease Control and Prevention. Syphilis and HIV: a dangerous duo affecting gay and bisexual men. 2012. Available from: http://blog.aids.gov/2012/12/syphilis-and-hiv-a-dangerous-duo-affecting-gay-and-bisexual-men.html#sthash.4qzEu24O.dpuf.
  72. Bachmann LH, Hobbs MM, Seña AC, et al. Trichomonas vaginalis genital infections: progress and challenges. Clin Infect Dis. 2011;53 Suppl 3:S160–72.
  73. Francis SC, Kent CK, Klausner JD, et al. Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005–2006. Sex Transm Dis. 2008;35:797–800.
  74. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr. 2010;55(5):565–71.